Cargando…
Anti-fibrotic therapy and lung transplant outcomes in patients with idiopathic pulmonary fibrosis
BACKGROUND: It is unclear whether continuing anti-fibrotic therapy until the time of lung transplant increases the risk of complications in patients with idiopathic pulmonary fibrosis. OBJECTIVES: To investigate whether the time between discontinuation of anti-fibrotic therapy and lung transplant in...
Autores principales: | Astor, Todd L., Goldberg, Hilary J., Snyder, Laurie D., Courtwright, Andrew, Hachem, Ramsey, Pena, Tahuanty, Zaffiri, Lorenzo, Criner, Gerard J., Budev, Marie M., Thaniyavarn, Tany, Leonard, Thomas B., Bender, Shaun, Barakat, Aliaa, Breeze, Janis L., LaCamera, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126649/ https://www.ncbi.nlm.nih.gov/pubmed/37073794 http://dx.doi.org/10.1177/17534666231165912 |
Ejemplares similares
-
Association between dexmedetomidine use for the treatment of alcohol withdrawal syndrome and intensive care unit length of stay
por: Yavarovich, Ekaterina R., et al.
Publicado: (2019) -
Alemtuzumab as a Therapy for Chronic Lung Allograft Dysfunction in Lung Transplant Recipients With Short Telomeres
por: Trindade, Anil J., et al.
Publicado: (2020) -
1-year outcomes for lung transplantation recipients with non-alcoholic fatty liver disease
por: Trindade, Anil J., et al.
Publicado: (2021) -
1600. An Optimal Respiratory Syncytial Virus (RSV) Treatment in Lung Transplant Recipients: Oral Ribavirin, Inhaled Ribavirin, or Conservative Approach
por: Permpalung, Nitipong, et al.
Publicado: (2018) -
1599. Rejection Outcomes in Lung Transplant Recipients Post Respiratory Syncytial Virus Infections
por: Permpalung, Nitipong, et al.
Publicado: (2018)